Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy.
- DOI
- 10.1016/j.critrevonc.2026.105598
- Published
- 2026 Sep 16
- Container
- Critical reviews in oncology/hematology
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.critrevonc.2026.105598,
title = {Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy.},
author = {Easmin S and Palai S and Saha S and Bhattacharyya M and Sen S and Jana TS and Gucchait K and Mondal S and Sahoo A and Das P},
year = {2026},
journal = {Critical reviews in oncology/hematology},
doi = {10.1016/j.critrevonc.2026.105598},
url = {https://doi.org/10.1016/j.critrevonc.2026.105598}
}RIS
TY - JOUR TI - Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy. AU - Easmin S AU - Palai S AU - Saha S AU - Bhattacharyya M AU - Sen S AU - Jana TS AU - Gucchait K AU - Mondal S AU - Sahoo A AU - Das P PY - 2026 JO - Critical reviews in oncology/hematology DO - 10.1016/j.critrevonc.2026.105598 UR - https://doi.org/10.1016/j.critrevonc.2026.105598 ER -
APA
S, E., S, P., S, S., M, B., S, S., TS, J., K, G., S, M., A, S., & P, D. (2026). Penpulimab: A next-generation Fc-engineered PD-1 inhibitor in cancer immunotherapy.. Critical reviews in oncology/hematology. https://doi.org/10.1016/j.critrevonc.2026.105598
Source records
- pubmed · retrieved 2026-09-25T12:40:46.613Z
- europe-pmc · retrieved 2026-09-25T12:40:47.384Z